W.L. Gore & Associates defends patent foramen ovale closure devices after St. Jude's RESPECT study, which failed to meet clinical endpoints, demonstrates that proper patient inclusion criteria are "imperative" to successful treatment.
W.L. Gore & Associates researchers defended St. Jude Medical's (NYSE:STJ) failed patent foramen closure device study, arguing that, although the study failed to meet its clinical endpoints it highlighted the need for better patient inclusion criteria.
St. Jude last month lost some Wall Street love after it unveiled the results of its RESPECT trials, which showed that the company's Amplatzer heart implant failed to significantly reduce cryptogenic stroke compared with standard treatment with drugs.